All In Biotech

Drug Trial Radar · NCT00249873

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)

A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation

Last checked: Nov 19, 2026Latest source record: Jun 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 7,554 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

7,554

Actual

Start

Jun 2003

Primary completion

Mar 2009

Study completion Mar 2009

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
Nov 7, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if the combination of clopidogrel 75mg once daily (od) plus aspirin 100mg daily (recommended dose) is better than aspirin alone (100mg daily recommended dose) for preventing vascular events such as stroke and heart attack during approximately three years of follow-up in patients with atrial fibrillation associated with at least one major risk factor of vascular event such as elderly, blood pressure increase, history of stroke or transient ischemic attack or left ventricular dysfunction etc. The study will also accept patients with atrial fibrillation and unwilling to take oral anticoagulant therapy.

Conditions

  • Atrial Fibrillation
  • Vascular Risk

Interventions

  • clopidogrel (SR25990C)Drug

    oral administration (tablets)

  • placeboDrug

    oral administration (tablets)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per AdjudicationTime frame: expected median follow-up of approximately 3 years

Locations

30 sites in 30 countries. Site status is shown where the registry gives one.

  • Sanofi-Aventis Administrative Office

    Bridgewater, New Jersey

  • Sanofi-Aventis Administrative Office

    Buenos Aires, Argentina

  • Sanofi-Aventis Administrative Office

    Macquarie Park, Australia

  • Sanofi-Aventis

    Vienna, Austria

  • Sanofi-aventis Administrative Office

    Diegem, Belgium

  • Sanofi-Aventis Administrative Office

    São Paulo, Brazil

  • Sanofi-Aventis Administrative Office

    Laval, Canada

  • Sanofi-Aventis Administrative Office

    Santiago, Chile

  • Sanofi-Aventis Administrative Office

    Prague, Czechia

  • Sanofi-Aventis Administrative Office

    Hørsholm, Denmark

  • Sanofi-Aventis Administrative Office

    Helsinki, Finland

  • Sanofi-Aventis Administrative Office

    Paris, France

  • Sanofi-Aventis Administrative Office

    Berlin, Germany

  • Sanofi-Aventis Administrative Office

    Athens, Greece

  • Sanofi-Aventis Administrative Office

    Causeway Bay, Hong Kong

  • Sanofi-Aventis Administrative Office

    Budapest, Hungary

  • Sanofi-Aventis Administrative Office

    Milan, Italy

  • Sanofi-Aventis Administrative Office

    Kuala Lumpur, Malaysia

  • Sanofi-Aventis Administrative Office

    México, Mexico

  • Sanofi-Aventis Administrative Office

    Gouda, Netherlands

  • Sanofi-Aventis Administrative Office

    Lysaker, Norway

  • Sanofi-Aventis Administrative Office

    Warsaw, Poland

  • Sanofi-Aventis Administrative Office

    Porto Salvo, Portugal

  • Sanofi-Aventis Administrative Office

    Singapore, Singapore

  • Sanofi-Aventis Administrative Office

    Midrand, South Africa

  • Sanofi-Aventis Administrative Office

    Barcelona, Spain

  • Sanofi-Aventis Administrative Office

    Bromma, Sweden

  • Sanofi-Aventis Administrative Office

    Geneva, Switzerland

  • Sanofi-Aventis Administrative Office

    Taipei, Taiwan

  • Sanofi-Aventis Administrative Office

    Guildford Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.